Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases

Sosnik, Alejandro; Seremeta, Katia Pamela; Imperiale, Julieta Celeste

doi:10.1517/17425247.2012.655268

Cited by 41 publications

(26 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rapidly advancing innovative technologies such as (oro-)dispersible, multiparticulate and chewable preparations offer the key advantages of solid dosage forms, together with the flexibility of dosing and ease of ingestion traditionally associated with liquids. Development of appropriate formulations is a global health challenge and the distinct 45 requirements in resource-limited settings also requires due consideration (Craig et al, 2009, Sosnik et al, 2012. The World Health Organization (WHO) has spearheaded various initiatives in the area of paediatric medicines, including the aptly named "Make Medicines Child Size" campaign.…”

Section: Introductionmentioning

confidence: 99%

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Ranmal¹,

Cram

Tuleu³

2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

A lack of evidence to guide the design of age-appropriate and acceptable dosage forms has been a longstanding knowledge gap in paediatric formulation development. The Children's Acceptability of Oral Formulations (CALF) study captured end-user perceptions and practices with a focus on solid oral dosage forms, namely tablets, capsules, chewables, orodispersibles, multiparticulates (administered with food) and mini-tablets (administered directly into the mouth). A rigorous development and testing phase produced age-adapted questionnaires as measurement tools with strong evidence of validity and reliability. Overall, 590 school children and adolescents, and 428 adult caregivers were surveyed across hospitals and various community settings. Attitudes towards dosage forms primarily differed based on age and prior use. Positive attitudes to tablets and capsules increased with age until around 14 years. Preference was seen for chewable and orodispersible preparations across ages, while multiparticulates were seemingly less favourable. Overall, 59.6% of school children reported willingness to take 10mm diameter tablets, although only 32.1% of caregivers perceived this size to be suitable. While not to be taken as prescriptive guidance, the results of this study provide some evidence towards rational dosage form design, as well as methodological approaches to help design tools for further evaluation of acceptability within paediatric studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Ranmal¹,

Cram

Tuleu³

2016

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Another disadvantage displayed by many antiprotozoals is the bitter taste that has a crucial role in the treatment of pediatric patients and that jeopardizes compliance and therapy efficacy [93]. Several research groups have proved that drug/CD complexes mask bitterness [94][95][96][97].…”

Section: Concentration Of Hpβ-cd (% W/v) Flux (μG/ml/cm 2 ) (Mean ± Sd)mentioning

confidence: 99%

Cyclodextrin Complexes for Treatment Improvement in Infectious Diseases

Imperiale

Sosnik

2015

Nanomedicine (Lond.)

Self Cite

View full text Add to dashboard Cite

Infectious diseases are a heterogeneous group of maladies that represent a serious burden to healthcare systems worldwide. Most of the available antimicrobial drugs display poor biopharmaceutical properties that compromise their effectiveness. Cyclodextrins (CDs) are cyclic oligosaccharides of glucopyranose formed by a variable number of repeating units that combine a hydrophilic surface with a hydrophobic cavity. The production of drug/CD complexes has become one of the most extensively investigated technology approaches to improve the stability, solubility, dissolution rate and bioavailability of drugs. The present work overviews the applications of CDs for the formulation of anti-infective agents along with the most relevant administration routes. Finally, an update on the complexes with CDs available on the market to treat infectious diseases is presented.

show abstract

“…The prolonged HAART therapy showed a low patient compliance, especially among the children. The approved antiretroviral drugs by regulatory agencies for pediatric use are in fact limited (Sosnik et al, 2012). Nelfinavir mesylate (NFV) is a non-peptidic HIV-1 protease inhibitor, which is the first of its kind recommended for pediatric use (Schuval, 2009).…”

Section: Introductionmentioning

confidence: 99%

Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect

Venkatesh

Baskaran

Karri

et al. 2015

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Nelfinavir mesylate (NFV) is an anti-viral drug, used in the treatment of Acquired Immunodeficiency Syndrome (AIDS). Poor oral bioavailability and shorter half-life (3.5-5 h) remain a major clinical limitation of NFV leading to unpredictable drug bioavailability and frequent dosing. In this context, the objective of the present study was to formulate NFV loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), which can increase the solubility and oral bioavailability along with sustained release of the drug. NFV loaded PLGA-NPs were prepared by nanoprecipitation method using PLGA and Poloxomer 407. The prepared NPs were evaluated for particle size, zeta potential, morphology, drug content, entrapment efficiency (EE) and in vitro dissolution studies. Oral bioavailability studies were carried out in New Zealand rabbits by administering developed NFV PLGA-NPs and pure drug suspension. PLGA-NPs prepared by using 1:4 ratio of drug and PLGA, with a stirring rate of 1500 rpm for 4 h. The prepared NPs were in the size of 185 ± 0.83 nm with a zeta potential of 28.7 ± 0.09 mV. The developed NPs were found to be spherical with uniform size distribution. The drug content and EE of the optimized formulation were found to be 36 ± 0.19% and 72 ± 0.47% respectively. After oral administration of NFV PLGA-NPs, the relative bioavailability was enhanced about 4.94 fold compared to NFV suspension as a control. The results describe an effective strategy for oral delivery of NFV loaded PLGA NPs that helps in enhancing bioavailability and reduce the frequency of dosing.

show abstract

Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases

Cited by 41 publications

References 142 publications

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children’s Acceptability of Oral Formulations (CALF) Study

Cyclodextrin Complexes for Treatment Improvement in Infectious Diseases

Fabrication and in vivo evaluation of Nelfinavir loaded PLGA nanoparticles for enhancing oral bioavailability and therapeutic effect

Contact Info

Product

Resources

About